干扰素调节因子5:一种新的炎症标记物和性结肠炎的有前途的治疗标
Karima Farrag1, Aysegül Aksan2, Marina Korotkova3,4
1Medical Clinic 1, University Hospital, Goethe University Frankfurt, 60594 Frankfurt am Main, Germany.
Biomedicines
|September 27, 2025
概括
干扰素调节因子5 (IRF5) 在性结肠炎 (UC) 患者中升高,与疾病活性相关. 这一发现表明IRF5可能作为炎症性肠病 (IBD) 治疗干预的生物标志物.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 炎症性肠病 (IBD),包括克罗恩病和性结肠炎 (UC),涉及具有复杂遗传和环境起源的慢性胃肠道炎症.
- 目前的IBD疗法显示出可变的疗效,突出显示出由于疾病异质性而需要预测生物标志物.
- 超过200个遗传位点与IBD有关,这表明其发病过程中存在强烈的遗传成分.
研究的目的:
- 调查干扰素调节因子5 (IRF5) 在IBD病变发生过程中的作用.
- 具体评估性结肠炎 (UC) 患者的IRF5表达.
主要方法:
- 分析了30名UC患者和8名健康对照者的结肠活检.
- 免疫制以量化IRF5在结肠组织中的表达.
- IRF5阳性细胞与疾病活性和calprotectin水平的统计相关性.
主要成果:
- 与对照人群相比,在炎症的UC粘膜中观察到显著增加的IRF5阳性巨细胞.
- 在IBD患者中,IRF5表达与疾病活性和calprotectin水平正相关.
- 较高的IRF5水平与增加的肠道炎症有关.
结论:
- IRF5表达与UC的疾病活性有显著的相关性.
- IRF5成为潜在的新生物标志物,用于指导IBD治疗干预.
- 需要进一步的研究来阐明IRF5的致病机制和IBD的治疗潜力.
更多相关视频
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
521
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Drugs for Treatment of Ulcerative Colitis in IBD
460
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
460
Inflammatory Bowel Disease I: Ulcerative Colitis
903
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
903
Inflammatory Bowel Disease II: Crohn's Disease
960
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
960


